(4-((1-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)-1-methylethyl)thio)-2,6-bis(1,1-dimethylethyl)phenoxy)acetic acid,
AGIX 4207,
AGIX-4207,
AGIX4207,
camobucol,
ylgucpd100bdh,
Camobucol,
216167-92-9,
AGIX-4207,
UNII-FZ7798X3IR,
FZ7798X3IR,
Camobucol (USAN/INN),
Camobucol [USAN:INN],
SCHEMBL4734553,
CHEMBL2104958,
AGIX 4207,
DTXSID70176004,
FGBGXESDYFKUFX-UHFFFAOYSA-N,
ZINC3937466,
CS-6701,
ACM216167929,
HY-14916,
D06570,
(4-(((1-(((3,5-bis(1,1-Dimethylethyl)-4-hydroxyphenyl)sulfanyl)-1-methylethyl)sulfanyl)-2,6-bis(1,1-dimethylethyl)phenoxy)acetic acid,
{2,6-Di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-1-methyl-ethylsulfanyl]-phenoxy}-acetic acid,
2-(4-((1-((3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)-1-methylethyl)thio)-2,6-bis(1,1-dimethylethyl)phenoxy)acetic acid,
Acetic acid, (4-((1-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)-1-methylethyl)thio)-2,6-bis(1,1-dimethylethyl)phenoxy)-,
D0Q9ZD,
AGIX-4207 IV,
CID9875498,
V-protectant (rheumatoid arthritis), AtheroGenics,
2-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)s,